Management of Hypertension in Dialysis Patients

Introduction to Hypertension Management

• Hypertension management is crucial in dialysis patients, with a focus on individualized targets and careful monitoring, as emphasized by the American College of Cardiology and Kidney Disease: Improving Global Outcomes (KDIGO) guidelines 1, 2
• The American Heart Association recommends ACE inhibitors to improve survival in patients with heart failure and reduced left ventricular ejection fraction, which can be applicable to dialysis patients 3

Benefits and Risks of ACE Inhibitors

• ACE inhibitors may preserve residual kidney function, especially in peritoneal dialysis patients, according to the National Kidney Foundation 4
• Dialysis patients are at higher risk of developing hyperkalemia with ACE inhibitors, as stated by the American Heart Association 5
• ACE inhibitors can be used in dialysis patients, but require careful dosing, monitoring, and consideration of specific risks including hypotension and hyperkalemia, as recommended by the American College of Cardiology 3

Dosing and Administration Considerations

• Choose non-dialyzable ACE inhibitors when possible to maintain stable therapy, as recommended by the American College of Cardiology 5
• Start with low doses and titrate carefully, as suggested by the Journal of the American College of Cardiology 6
• Individualize dosing schedules around dialysis sessions to avoid intradialytic hypotension, as recommended by the American College of Cardiology 3
• Non-dialyzable medications, such as clonidine, carvedilol, labetalol, most calcium channel blockers (CCBs), and angiotensin receptor blockers (ARBs), are preferred, while dialyzable medications, such as some ACE inhibitors and beta blockers, may require post-dialysis dosing 3
• Antihypertensive drugs should be administered preferentially at night to reduce nocturnal BP surge and minimize intradialytic hypotension, as recommended by the American Journal of Kidney Diseases guidelines 3

Monitoring and Contraindications

• Assess for symptoms of hypotension, especially during dialysis sessions, as recommended by the American College of Cardiology 3
• Avoid using ACE inhibitors with polyacrylonitrile dialysis membranes due to risk of anaphylactoid reactions, as stated by the American Heart Association 5
• Regular monitoring of volume status is essential in hemodialysis patients with hypertension, and regular monitoring of serum potassium is essential to prevent hyperkalemia when using ACE inhibitors like lisinopril in dialysis patients 2, 4, 3
• Blood pressure should be checked pre-dialysis, intradialytic, and post-dialysis to monitor for hypotension and hypertension, with monitoring of predialysis, intradialytic, and postdialysis blood pressure crucial to assess for intradialytic hypotension or hypertension 2, 4, 3, 7

Alternative Therapies

• Beta-blockers, particularly carvedilol, have stronger evidence for mortality benefit in dialysis patients with heart failure, as recommended by the American College of Cardiology 3
• Calcium Channel Blockers (CCBs) have demonstrated improved Glomerular Filtration Rate (GFR) and kidney survival in kidney transplant patients, with a Class of Recommendation (COR) IIa and Level of Evidence (LOE) B-R, according to the American College of Cardiology 1
• Angiotensin-Converting Enzyme (ACE) inhibitors or Angiotensin Receptor Blockers (ARBs) may help preserve residual kidney function in patients with kidney disease, as recommended by the American College of Cardiology 2

Medication Recommendations

• First-line medications for hypertension in dialysis patients are ACE inhibitors or ARBs, which have benefits including regression of LVH, reduced sympathetic activity, and improved endothelial function, according to the American Journal of Kidney Diseases guidelines 3
• Second-line medications for hypertension in dialysis patients are Calcium channel blockers, with non-dialyzable options preferred, as recommended by the American Journal of Kidney Diseases guidelines 3
• Third-line medications are Beta-blockers, particularly if cardiovascular disease is present, with non-dialyzable options like carvedilol preferred, although the strength of evidence for this is not specified 3

Resistant Hypertension Management

• Resistant hypertension is defined as BP >140/90 mmHg despite dry weight achievement and three antihypertensive agents, and management includes ensuring volume control, using combination therapy, and considering surgical or embolic nephrectomy as a last resort, as recommended by the American Journal of Kidney Diseases guidelines 3, 4
• Additional agents for resistant hypertension include Alpha-adrenergic blockers and Minoxidil (for severe cases), as suggested by the American Journal of Kidney Diseases guidelines 3

Lifestyle Modifications

• Dietary sodium restriction is recommended at 2-3 g/day with regular dietitian counseling (every 3 months), as advised by the American Journal of Kidney Diseases guidelines 3
• Maximizing peritoneal ultrafiltration and urine output through strategies such as using icodextrin for long dwells, shortening dwell time with glucose-based solutions, and using diuretics if residual kidney function exists, as suggested by the Kidney International 4

Common Mistakes to Avoid

• Neglecting volume control before intensifying medication therapy, failing to adjust medications for dialysis schedule, administering dialyzable medications before dialysis sessions, excessive BP reduction leading to intradialytic hypotension, and not monitoring for hyperkalemia with ACE inhibitors/ARBs, as noted by the American Journal of Kidney Diseases guidelines 3